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Purpose: Type II endoleak after endovascular abdominal aortic aneurysm repair is a failure of aneurysm sac exclusion with
unknown long-term consequences. Elevated aneurysm sac pressures documented in these patients have led us to
aggressively treat type II endoleaks with percutaneous transluminal coil embolization (PTCE). The purpose of this study
was to evaluate the results and the mechanisms of failure of PTCE for type II endoleak.
Methods: One hundred ninety-one patients underwent endograft repair of infrarenal aortic aneurysms. Twenty-three of 28
patients with persistent primary (>3 months) or secondary (new-onset) endoleak underwent angiography; 14 of these
patients had type II endoleaks. We reviewed our endovascular registry data, hospital charts, and radiologic studies of
patients with type II endoleaks and analyzed the results in those treated with PTCE of the inflow vessel.
Results: All 14 patients with type II endoleaks were men, with a mean age of 76.7 years and a mean preoperative maximal
aneurysm diameter of 5.7 1.0 cm. The type II endoleak was primary in 12 patients (86%) and secondary in two patients
(14%) and iliolumbar in 11 patients (78%) and mesenteric in three patients (21%). Although a dominant affluent collateral
channel (inosculation) was apparent in eight patients (57%), six patients (43%) showed a network of collateral vessels
(retiform anastomosis). In six patients (43%), angiography revealed a second or “outflow” vessel indicative of a complex
endoleak. In four patients with retiform iliolumbar type II endoleaks, PTCE was not attempted because of the retiform
nature of the endoleak. The remaining 10 patients underwent PTCE, with coil deployment in all 10 and apparent initial
technical success in nine patients. Follow-up computed tomographic scans revealed persistent endoleaks in six patients
(60%). Mechanisms of failure included persistent flow through the coils in the treated vessel in two patients, development
of a retiform anastomosis around the coiled vessel in three patients, and development of a new mesenteric endoleak after
successful occlusion of an iliolumbar endoleak in one patient. Two patients underwent repeat PTCE with successful
aneurysm sac exclusion in one. Internal iliac artery injury complicated one of the 12 PTCEs, and the resulting
pseudoaneurysm was successfully treated with PTCE. Angiographic visualization of an outflow vessel (complex endoleak)
was associated with PTCE failure (P  .008).
Conclusion: PTCE of type II endoleaks has a high failure rate because of multiple anatomic mechanisms. (J Vasc Surg
2002;36:485-91.)
A type II endoleak after endoluminal repair of an ab-
dominal aortic aneurysm (er-AAA) refers to collateral
blood flow retrograde into the sac from patent aortic
branch vessels, usually the lumbar or the inferior mesenteric
artery (IMA).1 Although completion angiograms after en-
dograft implantation commonly show one or more patent
lumbar arteries or the IMA, most of these aortic side
branches will thrombose in the early postoperative period.
Continued patency of any branch vessel in continuity with
the aneurysm sac is defined as a type II endoleak.
Because of the limited follow-up available, the manage-
ment of type II endoleaks after er-AAA remains controver-
sial. Nonetheless, a type II endoleak clearly indicates a
failure of aneurysm sac exclusion, and both clinical and
laboratory investigations have documented elevated sac
pressures.2,3 Moreover, continued aneurysm enlargement
and post–er-AAA rupture have been reported in patients
with persistent type II endoleaks.4-6 This evidence has led
our group to follow an aggressive management algorithm
of early angiography and percutaneous transluminal coil
embolization (PTCE) of type II endoleaks. Herein, we
present our results of PTCE and analyze the mechanisms of
failure of PTCE for type II endoleak.
METHODS AND MATERIALS
Study population and design. Between June 1997
and December 2001, 191 patients underwent successful
deployment of an aortic endograft at Southern Illinois
University School of Medicine and Memorial Medical Cen-
ter. The devices used included: AneuRx endograft system
(Medtronic/AVE, Inc, Santa Rosa, Calif), Excluder (WL
Gore and Associates, Inc, Flagstaff, Ariz), AneuRx AUI
(Medtronic/AVE, Inc), Talent endoluminal spring stent
graft (Medtronic, Inc, Sunrise, Fla), and Power Link Sys-
tem (Endologix, Inc, Irvine, Calif). Data from all patients
undergoing er-AAA were entered prospectively into an
endovascular registry. The surveillance protocol adopted at
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Southern Illinois University after er-AAA has been previ-
ously reported.7 All patients undergo computed tomo-
graphic (CT) scanning at 1 month. If the imaging at 1
month indicates the presence of an endoleak, a CT scan is
performed at 3 months after repair. An angiogram is per-
formed if an endoleak is still present at 3 months. If no
endoleak is noted on the 1-month scan, or on the 3-month
scan for those positive at 1 month, further follow-up CT
scans are performed at 6 months and 1 year and annually
thereafter. All patients with the development of secondary
(new-onset) endoleaks undergo angiography, and more
frequent CT scanning may be undertaken in patients who
have persistent endoleaks, undergo secondary interven-
tions, or show evidence of aneurysm enlargement.
Data from our endovascular registry, hospital records,
and clinic charts were reviewed for all patients with type II
endoleaks. CT scans and angiograms were reviewed by a
single radiologist (GB) blinded to the treatments and out-
comes. 2 and Student t tests were used to determine
differences between groups. Significance was assigned a P
value of .05 or less.
Classification of type II endoleak. A type II en-
doleak can be classified as primary or secondary. A primary
endoleak is detected on the 1-month CT scan and is pre-
sumed to have been present from the completion of the
endograft repair. A secondary endoleak develops after a
period of complete sac exclusion as determined with fol-
low-up imaging studies. Type II endoleaks can be further
classified by the angiographic anatomy as iliolumbar, mes-
enteric, or other. An iliolumbar type II endoleak originates
from the posterior trunk of the internal iliac artery that
supplies, via the iliolumbar branch or unnamed collaterals,
one or more ipsilateral lumbar arteries and the aneurysm
sac. A mesenteric type II endoleak originates from the middle
colic artery branch of the superior mesenteric artery that
fills a patent IMA and the aneurysm sac via the arc of Riolan
or the marginal artery, or more rarely the IMA may fill from
the pelvis via the superior rectal arteries. Rarely, endoleaks
can result from a patent accessory renal or middle sacral
artery and may be classified as other. We also have found it
useful to classify the character of the collateral pathway as a
retiform anastomosis or an inosculation. Retiform anasto-
mosis describes a collateral pathway composed of a network
of small arteries. Collateral blood flow through a single
relatively large dominant vessel is a phenomenon termed
inosculation (Fig).8 Finally, type II endoleaks may also be
classified as simple or complex. Simple endoleaks have only
one vessel in communication with the aneurysm sac,
whereas complex type II leaks have multiple communicating
vessels. Visualization of contrast exiting the aneurysm sac
through outflow vessels during selective angiography is
indicative of a complex type II endoleak.
Percutaneous transluminal coil embolization. Coil
embolization of type II endoleaks was performed in an
angiographic suite. Iliolumbar endoleaks were initially ap-
proached from the ipsilateral femoral artery; however, in
two patients, stable catheter positions could not be
achieved and a left brachial artery access site was used.
Mesenteric endoleaks were approached from either femoral
artery. In most cases, a 5F access sheath was used for
diagnostic angiography and anticoagulation was achieved
with 5000 U of heparin. If needed, the diagnostic sheath
was upsized to 6F or 8F to accommodate guiding catheters
A, Selective internal iliac artery angiogram shows iliolumbar type II
endoleak with single large collateral vessel (inosculation) filling
aneurysm sac (arrow). B, Selective internal iliac artery angiogram
shows iliolumbar type II endoleak composed of network of small
collateral vessels (retiform anastomosis).
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of various configurations, which were positioned in the
proximal superior mesenteric artery or internal iliac artery.
Superselective catheterization of the target ipsilateral lum-
bar artery or IMA was accomplished with a hydrophilic
coated 0.014 Transcend wire (Boston Scientific, Medi-
Tech, Boston, Mass) and a 3F Renegade fiber braided
microcatheter (Boston Scientific Cork, Ltd, Cork, Ireland).
Tornado embolization coils (Cook Group Company,
Bloomington, Ind), 3 to 5 mm in maximal diameter, were
used to embolize the aneurysm sac or the inflow vessel as
close to the aneurysm sac as possible.
RESULTS
Of the 191 patients who underwent er-AAA during
the study period, our surveillance protocol identified 28
patients (14.6%) with primary and secondary (new-onset)
endoleaks. In four patients, primary endoleaks detected at 1
month spontaneously resolved by 3 months. An additional
small secondary endoleak also resolved before angiography.
Diagnostic angiography was performed in the remaining 23
patients and revealed type I endoleaks in two patients and
type III endoleaks in three patients, with angiography
indeterminate in four patients and type II endoleaks in 14
patients.
All 14 patients with type II endoleaks were men, with a
mean age of 76  8.19 years (range, 63 to 90 years). AAA
characteristics and endografts used are given in Table I. The
type II endoleaks were primary in 12 patients (86%) versus
secondary in two patients (14%) and iliolumbar in 11
patients (78%) versus mesenteric in three patients (21%).
Although a dominant collateral channel (inosculation) was
apparent in eight patients (57%), six patients (43%) showed
a retiform anastomosis (Fig). In six patients (43%), angiog-
raphy revealed a second or outflow vessel indicative of a
complex endoleak.
Four patients with small, retiform, iliolumbar type II
endoleaks were not treated because catheterization of the
inflow lumbar artery was not considered technically feasible
because of the retiform characteristics of the collateral
network. Spontaneous resolution of the endoleak occurred
in one of the four patients. In the remaining three patients,
aneurysm sac diameters have remained stable or decreased
in size (mean diameter change, 3 mm). Two of the four
untreated patients died in follow-up of causes unrelated to
the aortic aneurysm.
Ten patients underwent PTCE, with coil deployment
in all 10 and apparent initial technical success in nine
patients (Table II). One patient had a technically inade-
quate PTCE with a single coil placed in a proximal internal
iliac branch supplying a retiform endoleak. Follow-up CT
scans revealed persistent endoleaks in six of the 10 treated
patients. All six patients underwent repeat angiographic
evaluation, which revealed multiple mechanisms of failure
of PTCE to achieve aneurysm sac exclusion.
In one patient, angiography revealed successful oblit-
eration of the treated iliolumbar endoleak but the develop-
ment of a new mesenteric endoleak. This mesenteric en-
doleak, which may have contributed to the endoleak
initially but was not evident on previous transfemoral an-
giograms, was successfully treated with repeat PTCE with
complete resolution of all endoleak on follow-up CT scan.
In two patients, angiography showed persistent blood
flow through the coils of the treated endoleak vessels. In
one case, continued patency of a thoroughly coiled IMA
was seen in a patient who needed anticoagulation therapy
for a prosthetic heart valve. At 24 months of follow-up, CT
scanning has documented a stable aneurysm diameter in
this patient with no further intervention. The patient with a
technically inadequate initial PTCE had persistent flow
through the single proximally deployed coil. Follow-up CT
scans in this patient documented a 0.5-cm increase in
aneurysm diameter that prompted a second PTCE with
multiple 3-mm coils deployed distally in the endoleak chan-
nels. No further growth of the aneurysm sac has been noted
despite persistence of the endoleak after 9 months of fol-
low-up.
In the remaining three patients, angiography showed
persistent iliolumbar endoleaks caused by the new develop-
ment of a retiform anastomosis around the previously
coiled vessel. None were considered amenable to further
coil embolization. One of these three patients had a signif-
icant (0.7 cm) increase in aneurysm sac diameter, and
translumbar sac embolization is planned.
Overall, PTCE was performed 12 times in 10 patients
and was successful in thrombosis of the treated endoleak
vessel in six (50%). No significant differences were found
between successful and failed PTCE procedures in regards
to patient age, type of endograft implanted, preoperative
aneurysm diameter, number of lumbar arteries present, and
IMA patency. No difference in outcomes was found be-
tween successful and failed PTCE with regard to the num-
ber of coils deployed (10.3 4 versus 7.0 4) or whether
coils were placed into the aneurysm sac itself (2/4, 50%
versus 2/6, 33%) nor with regard to any classification of the
endoleak, whether primary versus secondary, iliolumbar
versus mesenteric, or retiform versus inosculant. The failure
of PTCE was significantly higher for complex endoleaks (ie,
cases where an aneurysm sac outflow vessel was angio-
graphically visualized; 5/6, 83% versus 1/6, 17%; P 
.008).
Table I. Demographics, preoperative AAA
characteristics, and endograft devices used in 14 patients
with type II endoleaks
Patient and AAA characteristics
Age (y; mean  standard deviation) 76.3  8
Preoperative AAA diameter (mm  SD) 57  9.9
No. of patent lumbar arteries 4.4  1.1
Preoperative patency of IMA 8 (57%)
Type of endograft used
AneuRx bifurcated 10 (71%)
AneuRx AUI 2 (14%)
Excluder 1 (7%)
Talent 1 (7%)
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In comparison of the preoperative and last follow-up
CT scan measurements of maximum aneurysm diameter for
all 14 patients with type II endoleaks (mean follow-up time,
18.2 months; range, 3 to 36 months), no significant differ-
ence in the change in aneurysm diameter after er-AAA was
found between patients with persistent (n  8) versus
sealed (n 6) endoleaks (mean change in maximum aneu-
rysm diameter, 0.3 mm versus 1.7 mm, respectively;
P  .37). There were no major complications or deaths
after PTCE. A dissection of the internal iliac artery was the
single minor complication. PTCE of the postdissection iliac
artery pseudoaneurysm was subsequently successful.
DISCUSSION
Although aneurysm ruptures after er-AAA have re-
sulted from type II endoleaks, the significance of persistent
type II endoleaks remains controversial.4-6 Some type II
endoleaks have been associated with aneurysm expansion,
whereas others have not.9-12 In the Eurostar series of more
than 2000 patients, a persistent type II endoleak was found
to be a significant risk factor for late conversion, although
not aneurysm rupture, and was associated with a combined
rupture/conversion rate of 5.3%.13,14 In animal models
with type II endoleaks, systemic sac mean and pulse pres-
sures were found to correlate with the diameter of the
patent collateral vessel.15,16 Similar results also have been
reported in mechanical endoleak models.3,17 In addition,
systemic or near systemic sac pressures have been measured
in patients with type II endoleaks associated with aneurysm
enlargement with selective IMA catheterizations and with
translumbar punctures.2,18 We believe that the current
evidence strongly supports an aggressive approach to oblit-
erating type II endoleaks, although the long-term effective-
ness of the prevailing treatments for type II endoleak re-
mains uncertain.
Since first reported in 1997, PTCE has emerged as the
main treatment of type II endoleak.19 In most patients in
whom angiography shows an inosculant collateral pathway
from either a mesenteric or internal iliac artery to the
aneurysm sac, microcatheter access to the sac and affluent
arterial orifice can be achieved and coil deployment success-
fully accomplished. Despite the high initial technical suc-
cess rate of PTCE, achieving complete aneurysm sac exclu-
sion with coiling the endoleak channel is far less certain. All
reports of endoleak PTCE to date have involved small
numbers of patients, and the rate of successful endoleak
resolution on follow-up imaging studies has varied widely
from 9% to 100%.18,20,21 In our series, initial technical
success was achieved in nine of 10 patients but was success-
ful in completely excluding the aneurysm sac in only four
patients. Repeated PTCE was performed in two patients, of
whom one had successful sac exclusion. Moreover, the
efficacy of successful PTCE in depressurization of the ex-
cluded sac is unknown. Although a decrease in aneurysm
size after successful embolization has been reported,22,23
continued sac pressure transmitted through the throm-
bosed endoleak (endotension) has been inferred as the
cause of continued aneurysm growth observed in some
patients despite successful PTCE.15,24 In this series, no
significant differences were found in either mean AAA
diameter change or the incidence of increased versus de-
creased AAA diameter between patients with persistent
(n  8) versus sealed (n  6) type II endoleaks. We
continue to follow all of these patients closely because the
long-term effects of persistent or sealed type II endoleaks
are still unknown.
Because CT scanning, duplex ultrasound scanning, and
three-dimensional reconstruction imaging cannot reliably
determine the type and source of an endoleak, all patients
found to have endoleaks with surveillance CT scanning
need angiography. Angiography allows type II endoleaks to
be further subclassified by the route of collateral flow as
iliolumbar or mesenteric types. Although these two collat-
eral pathways predominate, endoleaks from patent acces-
sory renal and middle sacral arteries have been reported.6,25
We further categorized type II endoleaks on the basis of the
character of the collateral anastomotic pathway as retiform
or inosculant, which may significantly impact on the role
and results of PTCE. Presuming there to be flow through
an endoleak, an inosculant type II endoleak, composed of a
Table II. Endoleak characteristics and mechanisms of failure of aneurysm sac exclusion in patients with type II
endoleaks treated with PTCE
Patient Type of endoleak treated
Successful sac
exclusion Mechanism of failure Repeat PTCE
1 Inosculant, iliolumbar No New mesenteric type II endoleak Yes
2 Inosculant, mesenteric No Persistent flow through coils* No
3 Retiform, iliolumbar No Persistent flow through coils† Yes
4 Inosculant, iliolumbar No Retiform collaterals around coiled artery No
5 Inosculant, iliolumbar No Retiform collaterals around coiled artery No
6 Inosculant, iliolumbar No Retiform collaterals around coiled artery No
7 Inosculant, mesenteric Yes
8 Inosculant, mesenteric Yes
9 Inosculant, iliolumbar Yes
10 Retiform, iliolumbar Yes
*Patient on chronic anticoagulation therapy for prosthetic heart valve.
†Technically inadequate PTCE.
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large dominant vessel, should theoretically transmit higher
arterial pressure to the aneurysm sac and increase the like-
lihood of expansion or rupture compared with a retiform
anastomosis. Moreover, inosculant type II endoleaks may
be more effectively treated with PTCE than retiform en-
doleaks because selective catheterization and coil deploy-
ment of a single large collateral vessel is more easily
achieved. For most of the retiform endoleaks we encoun-
tered, including four patients found initially to have reti-
form endoleaks and three patients in whom treatment failed
by retiform development, selective catheterization and coil
embolization was not considered to be technically feasible.
Of the two retiform endoleaks that were treated, one
resolved and one has persisted despite two PTCE proce-
dures. Because of the small numbers of patients, we were
not able to show a statistical difference in the outcome of
PTCE between retiform and inosculant endoleaks. Never-
theless, we believe that the character of the collateral anas-
tomotic pathway is important and that PTCE will rarely be
an effective treatment for retiform type II endoleaks.
An emerging model of type II endoleaks distinguishes
between simple endoleaks with one feeding vessel and
those with multiple vessels communicating with the aneu-
rysm sac, which may also have prognostic and treatment
implication. Conventional angiography may not ade-
quately visualize all endoleak branches and may underesti-
mate the complex nature of the endoleak.26,27 The inability
of PTCE to reliably occlude any but the one selectively
catheterized inflow vessel of a complex endoleak may ex-
plain some of our PTCE failures.
Baum et al27 have suggested that complex endoleaks
behave like arterial malformations and that translumbar
embolization is the treatment of choice. They reported that
direct translumbar embolization was effective in elimina-
tion of the endoleak in 92% of cases, as compared with an
80% failure rate for transluminal PTCE. In this model,
transluminal embolization of a single feeding vessel is inef-
fective, whereas translumbar embolization of the aneurysm
sac occludes the communication between the aortic side
branches analogous to embolization of the central nidus of
an arterial malformation and was successful in 12 of 13
patients.27 In our series, visualization of an outflow vessel
was predictive of PTCE failure. Because visualization of an
outflow vessel is indicative of a complex endoleak, this
model would explain our failures in this subset of patients.
Other techniques for treatment of type II endoleaks are
currently being investigated. Transluminal injections of
hystoacryl glue23 and ethylene-vinyl-alcohol copolymer,28
instead of coils, have been reported with success rates of
89% and 83%, respectively. However, complications of
transluminal injection of liquid agents have been observed,
including colonic ischemia and paraplegia.12,29 Successful
obliteration of a type II endoleak with laparoscopic clipping
of the offending collateral vessels has also been reported,
but morbidity and failure rates are unknown.30 Quite
promising are the reports by Walker, Macierewicz, and
Hopkinson31 of prevention of type II endoleaks with intra-
operative packing of the aneurysm sac with collagen sponge
at the time of endografting. This technique reliably
achieves complete aneurysm sac thrombosis, even in pa-
tients with numerous patent aortic side branches, drastically
reducing rate the incidence of type II endoleak.32
Currently the natural history and best treatment of type
II endoleaks are unknown. Although the number of pa-
tients reported herein was too small to make meaningful
comparisons between groups, the multiple mechanisms by
which endoleaks persisted after PTCE (Table II) suggest
that this treatment is inadequate and more than one
method of treatment may be needed to achieve aneurysm
sac exclusion. Continued experience may allow tailoring of
the treatment of type II endoleak to best match the ana-
tomic environment. Perhaps retiform pathways will be
more effectively obliterated with use of liquid agents. En-
doleaks with visible outflow vessels might respond better to
a translumbar approach by which both inflow and outflow
vessels can be addressed. Patients who need chronic anti-
coagulation therapy may benefit from intraoperative pack-
ing. Regardless of future advances in the treatment of type
II endoleaks, close monitoring and serious consideration of
conversion to open repair for aneurysm enlargement will
continue to be necessary to assure superior long-term re-
sults of er-AAA.
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DISCUSSION
Dr Alan Lumsden (Houston, Tex). Dr Solis and his col-
leagues examined the efficacy of coil embolization on the sealing of
endoleaks with defined type 2 anatomy. They elected to treat all
endoleaks regardless of aneurysm status. Most of these aneurysms
were stable in size. We recently reported an intervention on a
patient with a stable aneurysm where we performed IMA emboli-
zation complicated by colon ischemia and have completely
changed our approach to the presence of an asymptomatic en-
doleak in a stable aneurysm.
The Southern Illinois group had a surprisingly low type 2
endoleak; their overall endoleak was 14.6%, but only approxi-
mately half of these actually had type 2 endoleaks. Of the 28
patients who they identified with endoleaks, only 23 of 28 under-
went angiography, of which 14 had defined type 2 endoleak
anatomy. Angiography was performed in all of these patients with
an intent to treat with embolization in those who were amenable to
embolization. However, basically it was performed in only 10 of
the 14 patients because it was deemed to be technically not feasible
in four out of the 14; in other words, a 28% up-front intention to
treat failure rate. This was because of the presence of retiform
iliolumbar-type anatomy. The study really then examines the re-
maining 10 patients who were treated with embolization. How-
ever, a recurrent, or was it persistent, endoleak was found in nearly
60% of these cases. The failure modes of this embolization were
threefold: number one, appearance of new endoleaks through new
lumbar arteries, which were not previously visualized. In one case,
there was a persistent flow through coils, albeit in an anticoagu-
lated patient. And the third mechanism was that there were new
collaterals or, as they define it, retiform collaterals around a suc-
cessfully occluded artery. Each of these failure modes, of course,
has a different mechanism and begs several questions.
Most surgeons do not have a lot of experience with emboliza-
tion, and it is difficult to define what the end point is. When did you
determine that there were enough coils placed to successfully
achieve occlusion of that artery? How do you deem when the
embolization procedure is adequate?
The second question is given the very high likelihood that the
interventions are either not feasible or associated with failure,
ultimately this has not helped most of the patients that you
performed angiography on. Has this subsequently changed your
selection criteria for intervening on a patient with a demonstrated
type 2 endoleak and a nonexpanding aneurysm?
Question number three is, how aggressive are you in injecting
the sac to visualize outflow vessels, and do you think failure to
identify concurrent outflow vessels may have contributed to the
subsequent failures?
A final question is clearly there are many approaches to per-
forming embolization. Could you discuss the role for other agents,
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such as thrombin injection, onyx, glue, or have you changed a
direct sac puncture?
My final question is do you think there is a role for laparo-
scopic ligation of the inferior mesenteric artery? That has become a
preferred method of intervening when a type 2 endoleak anatomy
is based upon reflux in IMA.
Thank you for the privilege of discussing this paper.
Dr Maurice M. Solis. Thank you very much, Alan. Regard-
ing the question of how many coils we put in and when do we
know that we have adequately occluded the vessel, it is completely
subjective. We essentially keep deploying coils until there appears
to be a large collection of coils in the leak. There is absolutely no
science behind that. In fact, we do not even use the presence of
continued flow through the coils as an endpoint because generally
these patients are anticoagulated during the procedure. We com-
monly do not see the vessel completely during the procedure.
Has our high failure rate changed our thoughts on intervening
on these patients? No. We still feel that the current evidence
suggests that a type 2 endoleak is a pressurized sac and is going to
be associated with a poor prognosis and aneurysm expansion, and
we do not really wait to see aneurysm expansion. We try to treat
these aggressively. However, it is changing how we intervene on
these patients because we are going to translumbar puncture, and
we are looking at the other agents, although we have no experience
with tissue glues, or with thrombin injections. Your experience
with the thrombin injections has actually tempered our enthusiasm
for that technique.
In regards to laparoscopic clipping of the IMA, in our experi-
ence the IMA seems to be the easiest and most reliable to embolize
and so we are going to continue embolizing the IMA endoleaks. I
think coil embolization is more reliable for mesenteric endoleaks
that are always inosculant via a large marginal artery collateral.
Dr Frank Veith (Bronx, NY). I enjoyed this paper. We have
had a long interest in type 2 endoleaks and regard them as the
Achilles heel of endografting. As you know, some people think that
type 2 endoleaks are of no consequence. You obviously are very
aggressive and treat all or almost all of them. We are somewhere in
between. We think that a type 2 endoleak associated with a stable
or shrinking aneurysm probably does not need to be treated.
We have had 16 patients with persistent type 2 endoleaks, and
in 6 of those, there has been AAA enlargement, while in the others
the AAAs are stable or shrinking. Like you, we started out with
transarterial embolization and were very aggressive about it. How-
ever, it often does not work for the reasons that you put forth. We
consider type 2 endoleaks either complex with multiple feeding
vessels or simple with to and fro input. It is the complex ones that
cannot always be treated by transarterial embolization, at least in
our experience. So we have gone to translumbar techniques, and
some of these cases have been extraordinarily gratifying when we
have actually been able to put the catheter into the IMA, into the
lumbars, and embolize them directly. However, sometimes one
cannot do that and then one puts the coils or glue right into what
I call the engine room on the nidus. In many cases, this has resulted
in resolution of the endoleak, but we have also occasionally been
frustrated with translumbar techniques. Occasionally we cannot
get into the engine room, we certainly cannot always get into the
branches, and some of the patients’ leaks have persisted. I have a
couple of questions for you.
One of the question is, how many or what percentage of these type
2 endoleaks are associated with aneurysm enlargement? And rupture? I
have tried over the years to collect ruptures. You mentioned in one of
your slides ruptures. I have six cases, including one of our own, where
rupture has occurred. However, as you know, those who say these are
benign, they say, oh, well, they never rupture. Well, they certainly do, and
I would be interested in knowing what percentage of type II leaks do you
think enlarge and what is the incidence of rupture? How many cases have
you been able to collect with rupture?
Dr Solis. We have not seen any ruptures. Regarding the
number of patients that have enlarged of the 14 patients that had
type 2 endoleaks, we ended up with six sealed endoleaks and the
others have persistent endoleaks, either because they were not
treated or they were treated and failed. In the sealed group, one has
had a small, probably insignificant increase. In the persistent group,
one has had significant increase and underwent translumbar emboli-
zation last week. Two have had minor, 2 or 3 mm, increases that we
are watching. So, aneurysm increase regardless of whether the en-
doleak has persisted or sealed has occurred in the minority of cases.
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